Making more of enzyme A1, which tamps down inflammation, available could help treat diabetic retinopathy and retinopathy of prematurity.
MCG scientists have early evidence that HBI-002, a low-dose oral compound developed by Hillhurst Biopharmaceuticals, can safely reduce oxidative stress and inflammation in the retina.